Merck: Approaching The Accumulation Phase With An Expanding Product Portfolio

Summary

• Keytruda sales totaled $5,795 million in Q1 2023, up 17% year-on-year, thanks partly to an increase in its indications for use.
• At the same time, Robert Davis does not actively use the share buyback program, and in the first quarter of 2023, Merck repurchased its shares for about $149 million.
• At the end of the first quarter of 2023, Merck's total debt was about $30.75 billion, a decrease of $3.88 billion from 2021.
• However, due to the declining AI hype in the media, we expect the S&P 500 to drop to$4292-$4300, eventually driving Merck's share price down to $104-105 in the next two months, after which the accumulation phase will begin.
• We continue our analytics coverage of Merck with an "outperform" rating for the next 12 months.

PeopleImages

On April 27, 2023, Merck (NYSE:MRK), one of the leaders in the pharmaceutical industry, released its financial results for the first quarter of 2023, which not only continued the trend of Wall Street analysts' expectations but also managed to demonstrate that the

Analyst’s Disclosure:I/we have a beneficial long position in the shares of TAK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sell securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.